Page last updated: 2024-11-02

pioglitazone and Aging

pioglitazone has been researched along with Aging in 26 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.

Research Excerpts

ExcerptRelevanceReference
"5 kg/m(2)) were randomly assigned to one of four intervention groups: pioglitazone or placebo and resistance training (RT) or no RT, while undergoing intentional weight loss via a hypocaloric diet."9.17Resistance training and pioglitazone lead to improvements in muscle power during voluntary weight loss in older adults. ( Carr, JJ; Isom, S; Kritchevsky, SB; Lyles, MF; Marsh, AP; Miller, GD; Miller, ME; Nicklas, BJ; Shea, MK; Vance Locke, RM, 2013)
"To compare bladder cancer incidence between patients initiating pioglitazone treatment and patients initiating treatment with dipeptidyl-peptidase-4 inhibitors [DPP-4s] or sulfonylureas."7.88Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes. ( Buse, JB; Garry, EM; Lund, JL; Pate, V; Stürmer, T, 2018)
"We used the F344 rat model of aging, and monitored behavioral, electrophysiological, and molecular variables to assess the effects of pioglitazone (PIO-Actos(R) a TZD) on several peripheral (blood and liver) and central (hippocampal) biomarkers of aging."7.76Effects of long-term pioglitazone treatment on peripheral and central markers of aging. ( Anderson, KL; Avdiushko, MG; Blalock, EM; Chen, KC; Cohen, DA; Gant, JC; Pancani, T; Phelps, JT; Popovic, J; Porter, NM; Searcy, JL; Thibault, O, 2010)
" Here, we found that the PPAR-gamma agonist pioglitazone protected against renal injury in aging; it reduced proteinuria, improved GFR, decreased sclerosis, and alleviated cell senescence."7.75The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury. ( Deleuze, S; Fogo, AB; Ma, LJ; Potthoff, SA; Yang, HC; Zuo, Y, 2009)
" The current study was designed to test the hypothesis that prolonged treatment of aging LY mice with the TZD, pioglitazone, alters the ovarian expression of genes that may impact reproduction."7.74Pioglitazone administration alters ovarian gene expression in aging obese lethal yellow mice. ( Brannian, JD; Diggins, M; Eyster, KM; Weber, M, 2008)
"Pioglitazone treatment significantly increased phosphorylated (p-) Akt but significantly reduced p-ERK1/2 and p-JNK."5.38PPAR-γ activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model. ( Aonuma, K; Hirayama, A; Igarashi, M; Ito, Y; Murakoshi, N; Seo, Y; Tada, H; Xu, D, 2012)
"5 kg/m(2)) were randomly assigned to one of four intervention groups: pioglitazone or placebo and resistance training (RT) or no RT, while undergoing intentional weight loss via a hypocaloric diet."5.17Resistance training and pioglitazone lead to improvements in muscle power during voluntary weight loss in older adults. ( Carr, JJ; Isom, S; Kritchevsky, SB; Lyles, MF; Marsh, AP; Miller, GD; Miller, ME; Nicklas, BJ; Shea, MK; Vance Locke, RM, 2013)
"To compare bladder cancer incidence between patients initiating pioglitazone treatment and patients initiating treatment with dipeptidyl-peptidase-4 inhibitors [DPP-4s] or sulfonylureas."3.88Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes. ( Buse, JB; Garry, EM; Lund, JL; Pate, V; Stürmer, T, 2018)
"We used the F344 rat model of aging, and monitored behavioral, electrophysiological, and molecular variables to assess the effects of pioglitazone (PIO-Actos(R) a TZD) on several peripheral (blood and liver) and central (hippocampal) biomarkers of aging."3.76Effects of long-term pioglitazone treatment on peripheral and central markers of aging. ( Anderson, KL; Avdiushko, MG; Blalock, EM; Chen, KC; Cohen, DA; Gant, JC; Pancani, T; Phelps, JT; Popovic, J; Porter, NM; Searcy, JL; Thibault, O, 2010)
" Here, we found that the PPAR-gamma agonist pioglitazone protected against renal injury in aging; it reduced proteinuria, improved GFR, decreased sclerosis, and alleviated cell senescence."3.75The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury. ( Deleuze, S; Fogo, AB; Ma, LJ; Potthoff, SA; Yang, HC; Zuo, Y, 2009)
" The current study was designed to test the hypothesis that prolonged treatment of aging LY mice with the TZD, pioglitazone, alters the ovarian expression of genes that may impact reproduction."3.74Pioglitazone administration alters ovarian gene expression in aging obese lethal yellow mice. ( Brannian, JD; Diggins, M; Eyster, KM; Weber, M, 2008)
"The role of insulin resistance in the impaired glucose-stimulated insulin release of Zucker fatty rats was investigated using the insulin-sensitizing thiazolidinedione drug pioglitazone."3.69Insulin secretory defect in Zucker fa/fa rats is improved by ameliorating insulin resistance. ( de Souza, CJ; Meglasson, MD; Robinson, DD; Ulrich, RG; Yu, JH, 1995)
"Pioglitazone treatment in adult BHR caused no detectable changes in antioxidant and detoxificant responses."1.51Age-dependent effect of PPARγ agonist pioglitazone on kidney signaling in borderline hypertensive rats. ( Dovinova, I; Grešová, L; Kvandova, M; Kvasnicka, P, 2019)
"The elderly patients with type 2 diabetes suffer more adverse drug events than young adults due to pharmacokinetic and pharmacodynamic changes associated with aging."1.48Benefits of combination low-dose pioglitazone plus fish oil on aged type 2 diabetes mice. ( Chiba, K; Hirako, S; Iizuka, Y; Kim, H; Matsumoto, A; Wada, M, 2018)
"Pioglitazone treatment significantly increased phosphorylated (p-) Akt but significantly reduced p-ERK1/2 and p-JNK."1.38PPAR-γ activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model. ( Aonuma, K; Hirayama, A; Igarashi, M; Ito, Y; Murakoshi, N; Seo, Y; Tada, H; Xu, D, 2012)
"Glyburide did not lower DPP-IV activity or glycosylated hemoglobin."1.32Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. ( Croom, DK; Lenhard, JM; Minnick, DT, 2004)

Research

Studies (26)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (7.69)18.2507
2000's8 (30.77)29.6817
2010's16 (61.54)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barger, JL1
Vann, JM1
Cray, NL1
Pugh, TD1
Mastaloudis, A1
Hester, SN1
Wood, SM1
Newton, MA1
Weindruch, R1
Prolla, TA1
Garry, EM1
Buse, JB1
Lund, JL1
Pate, V1
Stürmer, T1
Shen, D1
Li, H1
Zhou, R1
Liu, MJ1
Yu, H1
Wu, DF1
Chang, L1
Zhao, X1
Garcia-Barrio, M1
Zhang, J1
Eugene Chen, Y1
Iizuka, Y1
Kim, H1
Hirako, S1
Chiba, K1
Wada, M1
Matsumoto, A1
Nakashima, M1
Kinoshita, M1
Nakashima, H1
Kotani, A1
Ishikiriyama, T1
Kato, S1
Hiroi, S1
Seki, S1
Grešová, L1
Kvandova, M1
Kvasnicka, P1
Dovinova, I1
Prakash, A1
Kumar, A1
Abdel-Rahman, EM1
Okusa, MD1
Wang, P1
Li, B1
Cai, G1
Huang, M1
Jiang, L1
Pu, J1
Li, L1
Wu, Q1
Zuo, L1
Wang, Q1
Zhou, P1
Zhang, Z1
Yuan, H1
Zhao, H1
Qi, B1
Li, F1
An, L1
Nicolakakis, N2
Aboulkassim, T2
Ongali, B1
Lecrux, C1
Fernandes, P1
Rosa-Neto, P2
Tong, XK2
Hamel, E2
Akiyama, M1
Hatanaka, M1
Ohta, Y1
Ueda, K1
Yanai, A1
Uehara, Y1
Tanabe, K1
Tsuru, M1
Miyazaki, M1
Saeki, S1
Saito, T1
Shinoda, K1
Oka, Y1
Tanizawa, Y1
Yang, HC1
Deleuze, S1
Zuo, Y1
Potthoff, SA1
Ma, LJ1
Fogo, AB1
Blalock, EM1
Phelps, JT1
Pancani, T1
Searcy, JL1
Anderson, KL1
Gant, JC1
Popovic, J1
Avdiushko, MG1
Cohen, DA1
Chen, KC1
Porter, NM1
Thibault, O1
Aliaga, A1
Spyridopoulos, I1
Xu, D1
Murakoshi, N1
Igarashi, M1
Hirayama, A1
Ito, Y1
Seo, Y1
Tada, H1
Aonuma, K1
Marsh, AP1
Shea, MK1
Vance Locke, RM1
Miller, ME1
Isom, S1
Miller, GD1
Nicklas, BJ1
Lyles, MF1
Carr, JJ1
Kritchevsky, SB1
Takeda, K1
Toda, K1
Saibara, T1
Nakagawa, M1
Saika, K1
Onishi, T1
Sugiura, T1
Shizuta, Y1
Lenhard, JM1
Croom, DK1
Minnick, DT1
Pathan, AR1
Viswanad, B1
Sonkusare, SK1
Ramarao, P1
Brannian, JD1
Eyster, KM1
Weber, M1
Diggins, M1
Szöcs, Z1
Brunmair, B1
Stadlbauer, K1
Nowotny, P1
Bauer, L1
Luger, A1
Fürnsinn, C1
de Souza, CJ1
Yu, JH1
Robinson, DD1
Ulrich, RG1
Meglasson, MD1
Umeda, F1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Cerebrovascular Reactivity (CVR) Assessed With Functional Near Infrared Spectroscopy (fNIRS) as a Biomarker of Traumatic Cerebrovascular Injury (TCVI) Measured Longitudinally After Acute TBI in Military Personnel[NCT04058132]Phase 250 participants (Anticipated)Interventional2019-08-09Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for pioglitazone and Aging

ArticleYear
Effects of aging on renal function and regenerative capacity.
    Nephron. Clinical practice, 2014, Volume: 127, Issue:1-4

    Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Aging; Animals; Cellular Senescence; Disease Models, A

2014
Potential role of thiazolidinediones in older diabetic patients.
    Drugs & aging, 1995, Volume: 7, Issue:5

    Topics: Aged; Aging; Animals; Benzopyrans; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Glucose

1995

Trials

1 trial available for pioglitazone and Aging

ArticleYear
Resistance training and pioglitazone lead to improvements in muscle power during voluntary weight loss in older adults.
    The journals of gerontology. Series A, Biological sciences and medical sciences, 2013, Volume: 68, Issue:7

    Topics: Aged; Aging; Body Composition; Body Mass Index; Female; Follow-Up Studies; Humans; Hypoglycemic Agen

2013

Other Studies

23 other studies available for pioglitazone and Aging

ArticleYear
Identification of tissue-specific transcriptional markers of caloric restriction in the mouse and their use to evaluate caloric restriction mimetics.
    Aging cell, 2017, Volume: 16, Issue:4

    Topics: 2,4-Dinitrophenol; Adipose Tissue, White; Aging; Animals; Bezafibrate; Caloric Restriction; Carnitin

2017
Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:1

    Topics: Aged; Aged, 80 and over; Aging; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV I

2018
Pioglitazone attenuates aging-related disorders in aged apolipoprotein E deficient mice.
    Experimental gerontology, 2018, Volume: 102

    Topics: Age Factors; Aging; Animals; Anti-Inflammatory Agents; Antioxidants; Aortic Diseases; Atherosclerosi

2018
MitoNEET in Perivascular Adipose Tissue Prevents Arterial Stiffness in Aging Mice.
    Cardiovascular drugs and therapy, 2018, Volume: 32, Issue:5

    Topics: Adipose Tissue, Brown; Adiposity; Age Factors; Aging; Animals; Cardiovascular Diseases; Diet, High-F

2018
Benefits of combination low-dose pioglitazone plus fish oil on aged type 2 diabetes mice.
    Journal of food and drug analysis, 2018, Volume: 26, Issue:4

    Topics: Aging; Animals; Diabetes Mellitus, Type 2; Docosahexaenoic Acids; Drug Therapy, Combination; Eicosap

2018
Pioglitazone improves phagocytic activity of liver recruited macrophages in elderly mice possibly by promoting glucose catabolism.
    Innate immunity, 2019, Volume: 25, Issue:6

    Topics: Aging; Animals; CD11b Antigen; Cytokines; Escherichia coli; Escherichia coli Infections; Glucose; In

2019
Age-dependent effect of PPARγ agonist pioglitazone on kidney signaling in borderline hypertensive rats.
    General physiology and biophysics, 2019, Volume: 38, Issue:3

    Topics: Aging; Animals; Hypertension; Kidney; Pioglitazone; PPAR gamma; Rats

2019
Pioglitazone alleviates the mitochondrial apoptotic pathway and mito-oxidative damage in the d-galactose-induced mouse model.
    Clinical and experimental pharmacology & physiology, 2013, Volume: 40, Issue:9

    Topics: Acetylcholinesterase; Aging; Animals; Antioxidants; Apoptosis; Behavior, Animal; Brain; Caspase 3; C

2013
Activation of PPAR-γ by pioglitazone attenuates oxidative stress in aging rat cerebral arteries through upregulating UCP2.
    Journal of cardiovascular pharmacology, 2014, Volume: 64, Issue:6

    Topics: Aging; Animals; Cerebral Arteries; Human Umbilical Vein Endothelial Cells; Humans; Ion Channels; Mal

2014
PPARγ activation ameliorates postoperative cognitive decline probably through suppressing hippocampal neuroinflammation in aged mice.
    International immunopharmacology, 2017, Volume: 43

    Topics: Aging; Anilides; Animals; Brain-Derived Neurotrophic Factor; Cells, Cultured; Cognitive Dysfunction;

2017
Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2008, Sep-10, Volume: 28, Issue:37

    Topics: Acetylcholine; Acetylcysteine; Aging; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein

2008
Increased insulin demand promotes while pioglitazone prevents pancreatic beta cell apoptosis in Wfs1 knockout mice.
    Diabetologia, 2009, Volume: 52, Issue:4

    Topics: Aging; Animals; Apoptosis; Body Weight; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP;

2009
The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury.
    Journal of the American Society of Nephrology : JASN, 2009, Volume: 20, Issue:11

    Topics: Age Factors; Aging; Animals; Disease Progression; Kidney Diseases; Male; Pioglitazone; PPAR gamma; R

2009
Effects of long-term pioglitazone treatment on peripheral and central markers of aging.
    PloS one, 2010, Apr-29, Volume: 5, Issue:4

    Topics: Aging; Alzheimer Disease; Animals; Biomarkers; Brain; Hippocampus; Hypoglycemic Agents; Inflammation

2010
Intact memory in TGF-β1 transgenic mice featuring chronic cerebrovascular deficit: recovery with pioglitazone.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2011, Volume: 31, Issue:1

    Topics: Aging; Animals; Antioxidants; Blotting, Western; Cerebrovascular Circulation; Cerebrovascular Disord

2011
Is telomerase a potential target for vascular rejuvenation?
    Atherosclerosis, 2011, Volume: 216, Issue:1

    Topics: Aging; Animals; Aorta; Apoptosis; Cellular Senescence; Cytoprotection; Endothelial Cells; Enzyme Act

2011
PPAR-γ activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model.
    Journal of cardiovascular electrophysiology, 2012, Volume: 23, Issue:2

    Topics: Aging; Animals; Antioxidants; Apoptosis; Atrial Fibrillation; Cardiotonic Agents; Disease Models, An

2012
Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency.
    The Journal of endocrinology, 2003, Volume: 176, Issue:2

    Topics: Aging; Animals; Aromatase; Bezafibrate; Blood Glucose; Cholesterol; Estradiol; Glucose Tolerance Tes

2003
Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments.
    Biochemical and biophysical research communications, 2004, Nov-05, Volume: 324, Issue:1

    Topics: Aging; Animals; Blood Glucose; Cell Membrane; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptid

2004
Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats.
    Life sciences, 2006, Nov-02, Volume: 79, Issue:23

    Topics: Administration, Oral; Aging; Animals; Antibiotics, Antineoplastic; Brain Chemistry; Cognition; Demen

2006
Pioglitazone administration alters ovarian gene expression in aging obese lethal yellow mice.
    Reproductive biology and endocrinology : RB&E, 2008, Mar-18, Volume: 6

    Topics: Administration, Oral; Aging; Animals; Female; Gene Expression; Gene Expression Profiling; Intercellu

2008
Age-dependent development of metabolic derangement and effects of intervention with pioglitazone in Zucker diabetic fatty rats.
    The Journal of pharmacology and experimental therapeutics, 2008, Volume: 326, Issue:1

    Topics: Aging; Animals; Blood Glucose; Body Weight; Diabetes Mellitus; Pioglitazone; Rats; Rats, Zucker; Thi

2008
Insulin secretory defect in Zucker fa/fa rats is improved by ameliorating insulin resistance.
    Diabetes, 1995, Volume: 44, Issue:8

    Topics: Aging; Amino Acids; Animals; Blood Glucose; Fatty Acids, Nonesterified; Female; Glucose; Hypoglycemi

1995